Company Active LTD

Company profile

Absolute Antibody Limited

Antibody Sequencing, Engineering & Expression | Absolute Antibody

Absolute Antibody specializes in the sequencing, engineering, and recombinant production of antibodies. If you can describe it, we can make it.

CRN
08166456
Founded
2012
Age
13

Overview

Legal name
ABSOLUTE ANTIBODY LIMITED
Region
North East England
Registered address
WILTON CENTRE
WILTON
REDCAR
CLEVELAND
ENGLAND
TS10 4RF
Insolvency history
No

Corporate ownership

Updated 06 Jun 2026 16:52

1 level 1 ultimate controller
1
Company Active LTD
Absolute Antibody Limited
CRN 08166456
2
Direct and ultimate controller Active LTD

Company events

Reference milestones and recent Companies House filing stream events.

7 events
30 Sep
2026

Accounts due

Accounts Due

Next accounts due date

16 Aug
2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

02 Aug
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Dec
2024

Accounts filed

Accounts

Last accounts made up date

16 Aug
2024

Confirmation Statement With No Updates

Confirmation-statement

CS01 | Transaction MzQzMjUyNTA3NGFkaXF6a2N4

Published 16 Aug 2024 18:41

16 Aug
2024

Termination Director Company With Name Termination Date

Officers

TM01 | Transaction MzQzMjUyNDk2M2FkaXF6a2N4

Published 16 Aug 2024 18:34

02 Aug
2012

Incorporated

Inception

Company registered at Companies House

Public funding

5 awards
First funded
2013
Funded years
2013, 2017, 2018, 2020
Age at first award
0 years

Projects

2020 EU-Funded Lead participant

LIPOLOGIC

1 Oct 2020 to 30 Sep 2022

Awarded
£172,120
Total cost £286,933

Awaiting Public Project Summary

2018 Collaborative R&D

Point-of-care for stroke subtype diagnosis to enable rapid treatment

1 Dec 2018 to 28 Feb 2021

Awarded
£74,677
Total cost £106,681

"POCKiT diagnostics is a UK company focused on the research and development of point-of-care diagnostic devices. Our main target is to develop a device for diagnosis of brain stroke. Stroke is the third leading cause of death and the first cause of physical disability and dementia worldwide. In stroke, the brain is damaged by restricted blood flow to the ...

2018 Feasibility Studies

mAb manufacturing for future subunit vaccine platform

1 Mar 2018 to 28 Feb 2019

Awarded
£27,376
Total cost £39,109

A platform for rapidly producing rationally engineered vaccines is urgently required to combat the threat of epidemic or pandemic pathogen outbreaks. Most existing vaccines are multicomponent products that are challenging to manufacture. The slowest step is typically transfer from preclinical proof-of-concept to GMP manufacture for human use. Manufacturin...

2017 EU-Funded Lead participant

ABC2ALL

1 Feb 2017 to 28 Feb 2021

Awarded
£161,505
Total cost £269,175

Awaiting Public Project Summary

2013 GRD Proof of Concept Lead participant

Absolute Antibody Ltd - Next generation antibodies for research and diagnosis

1 May 2013 to 30 Apr 2014

Awarded
£99,804
Total cost £166,340

Antibodies are outstanding tools for biomedical research and essential components of a myriad of diagnostic tests. They are also the largest and fastest growing source of new drugs with 39 approved to date and hundreds more in the pipeline. The vast majority of therapeutic antibodies are made using recombinant DNA technology, which has enabled the enginee...

Product types

Collaborative R&D EU-Funded Feasibility Studies GRD Proof of Concept